Mesoblast (MESO) EBT (2015 - 2023)

Mesoblast (MESO) has 9 years of EBT data on file, last reported at -$142.2 million in Q2 2023.

• For the quarter ending Q2 2023, EBT rose 12.01% year-over-year to -$142.2 million; the trailing twelve-month figure through Jun 2023 stood at -$82.1 million (up 10.36% YoY), and the FY2025 full-year result was -$101.8 million, down 15.5% from the prior year.
• EBT declined to -$142.2 million in Q2 2023, from $18.6 million in the prior quarter.
• In the past five years, EBT ranged from a high of $26.0 million in Q4 2021 to a low of -$161.7 million in Q2 2022.
• A 5-year average of -$22.1 million and a median of -$23.0 million in 2019 frame the typical range for EBT.
• Across the five-year window, EBT soared 201.59% in 2021 and tumbled 630.69% in 2022, its largest moves.
• Tracing MESO's EBT over 5 years: stood at -$26.9 million in 2019, then advanced by 4.6% to -$25.6 million in 2020, then soared by 201.59% to $26.0 million in 2021, then slipped by 5.64% to $24.6 million in 2022, then slumped by 679.24% to -$142.2 million in 2023.
• Business Quant data shows MESO's EBT at -$142.2 million in Q2 2023, $18.6 million in Q1 2023, and $24.6 million in Q4 2022.